Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | TLR4 | O00206 | 4/20 | 0.44 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070897 | 0.91 | MAPK1 (0.50) | MAPK1TLR4ALDH1A1THRB | |
| SCHEMBL16070899 | 0.89 | TLR4 (0.52) | MAPK1CA2CA9TLR4ALDH1A1 | |
| SCHEMBL17208311 | 0.87 | TLR4 (0.57) | MAPK1CA2CA9TLR4SELP | |
| SCHEMBL9233216 | 0.80 | MAPK1 (0.60) | MAPK1CA2CA9TLR4CA1 | |
| SCHEMBL16773657 | 0.79 | TLR4 (0.60) | MAPK1TLR4SELP | |
| SCHEMBL10064893 | 0.78 | MAPK1 (0.54) | MAPK1TLR4ALDH1A1THRB | |
| SCHEMBL2791012 | 0.78 | MAPK1 (0.54) | MAPK1TLR4ALDH1A1THRB | |
| SCHEMBL2741377 | 0.75 | MAPK1 (0.50) | MAPK1TLR4ALDH1A1THRBSELP | |
| SCHEMBL17208459 | 0.74 | MAPK1 (0.87) | MAPK1CA2CA9TLR4CETP | |
| SCHEMBL16694432 | 0.74 | MAPK1 (0.87) | MAPK1CA2CA9TLR4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160021879-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160021879-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160021879-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014143620-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160021879-A1 | SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD | CHIT1, GMDS, NANS | MAPK1 1853/4885CA2 1965/4885CA9 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.